TD Asset Management Inc Has $53.52 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Key Points

• TD Asset Management Inc has increased its holdings in Ascendis Pharma A/S by 1.1%, owning approximately 343,390 shares valued at $53.52 million as of its latest SEC filing.
• Multiple institutional investors, including T. Rowe Price and RA Capital Management, have significantly raised their stakes in Ascendis Pharma A/S, indicating strong institutional interest.
• Analysts are optimistic about Ascendis Pharma, with firms like JPMorgan and Bank of America increasing their price targets, projecting a substantial upside for the stock.

TD Asset Management Inc boosted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 343,390 shares of the biotechnology company's stock after acquiring an additional 3,738 shares during the period. TD Asset Management Inc owned about 0.56% of Ascendis Pharma A/S worth $53,521,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S during the 4th quarter worth approximately $28,000. Quarry LP acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $96,000. Tower Research Capital LLC TRC boosted its holdings in shares of Ascendis Pharma A/S by 195.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after buying an additional 664 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $174,000. Finally, New Wave Wealth Advisors LLC acquired a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at $222,000.

Ascendis Pharma A/S Trading Up 4.0%

ASND stock traded up $6.67 during midday trading on Thursday, hitting $173.45. The stock had a trading volume of 232,897 shares, compared to its average volume of 482,237. The stock has a 50-day simple moving average of $170.92 and a 200 day simple moving average of $156.33. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00. The firm has a market capitalization of $10.61 billion, a price-to-earnings ratio of -27.73 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ASND. Cantor Fitzgerald reiterated an "overweight" rating and issued a $200.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. Wedbush upped their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 price objective on the stock. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Finally, Bank of America raised their price target on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and an average target price of $223.67.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.